CytomX Therapeutics Inc.

1.86-0.0800-4.12%Vol 866.28K1Y Perf -70.11%
Jun 28th, 2022 16:00 DELAYED
BID1.85 ASK1.93
Open1.94 Previous Close1.94
Pre-Market- After-Market1.93
 - -  0.07 3.76%
Target Price
10.00 
Analyst Rating
Strong Buy 1.00
Potential %
437.63 
Finscreener Ranking
★★★     49.41
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★+     43.39
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★+     42.57
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
5.89 
Earnings Rating
Strong Buy
Market Cap121.64M 
Earnings Date
4th Aug 2022
Alpha-0.03 Standard Deviation0.16
Beta0.76 

Today's Price Range

1.821.94

52W Range

1.517.53

5 Year PE Ratio Range

-10.70-6.80

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Neutral
Performance
1 Week
13.45%
1 Month
19.75%
3 Months
-27.34%
6 Months
-55.30%
1 Year
-70.11%
3 Years
-82.71%
5 Years
-87.41%
10 Years
-

TickerPriceChg.Chg.%
CTMX1.86-0.0800-4.12
AAPL137.44-4.2200-2.98
GOOG2 251.43-81.0200-3.47
MSFT256.48-8.4100-3.17
XOM91.502.47002.77
WFC40.18-0.0600-0.15
JNJ176.94-5.1800-2.84
FB196.640.99000.51
GE65.88-0.8300-1.24
JPM115.82-0.5600-0.48
Financial StrengthValueIndustryS&P 500US Markets
2.60
2.60
0.20
0.31
-
Leverage Ratio 3.50
ProfitabilityValueIndustryS&P 500US Markets
-
-130.20
-126.50
-107.40
-96.67
RevenueValueIndustryS&P 500US Markets
70.74M
1.08
2.62
15.26
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.35-0.37-5.71
Q04 2021-0.25-0.40-60.00
Q03 2021-0.30-0.35-16.67
Q02 2021-0.26-0.30-15.38
Q01 2021-0.29-0.2610.34
Q04 2020-0.35-0.3111.43
Q03 2020-0.36-0.3211.11
Q02 20200.34-0.34-200.00
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.3713.95Positive
9/2022 QR-0.3913.33Positive
12/2022 FY-1.4410.00Positive
12/2023 FY-1.615.29Positive
Next Report Date4th Aug 2022
Estimated EPS Next Report-0.37
Estimates Count6
EPS Growth Next 5 Years %-
Volume Overview
Volume866.28K
Shares Outstanding65.40K
Shares Float64.65M
Trades Count4.83K
Dollar Volume1.62M
Avg. Volume1.77M
Avg. Weekly Volume2.88M
Avg. Monthly Volume1.34M
Avg. Quarterly Volume1.09M

CytomX Therapeutics Inc. (NASDAQ: CTMX) stock closed at 1.94 per share at the end of the most recent trading day (a 2.11% change compared to the prior day closing price) with a volume of 1.54M shares and market capitalization of 121.64M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 146 people. CytomX Therapeutics Inc. CEO is Sean A. McCarthy.

The one-year performance of CytomX Therapeutics Inc. stock is -70.11%, while year-to-date (YTD) performance is -55.2%. CTMX stock has a five-year performance of -87.41%. Its 52-week range is between 1.505 and 7.5299, which gives CTMX stock a 52-week price range ratio of 5.89%

CytomX Therapeutics Inc. currently has a PE ratio of -1.30, a price-to-book (PB) ratio of 1.82, a price-to-sale (PS) ratio of 1.79, a price to cashflow ratio of 10.30, a PEG ratio of 2.32, a ROA of -26.02%, a ROC of -71.16% and a ROE of -89.23%. The company’s profit margin is -96.67%, its EBITDA margin is -126.50%, and its revenue ttm is $70.74 Million , which makes it $1.08 revenue per share.

Of the last four earnings reports from CytomX Therapeutics Inc., there were 0 positive earnings surprise and 4 negative earnings surprise. The company has EPS estimate of $-0.37 for the next earnings report. CytomX Therapeutics Inc.’s next earnings report date is 04th Aug 2022.

The consensus rating of Wall Street analysts for CytomX Therapeutics Inc. is Strong Buy (1), with a target price of $10, which is +437.63% compared to the current price. The earnings rating for CytomX Therapeutics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

CytomX Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

CytomX Therapeutics Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 9.16, ATR14 : 0.14, CCI20 : 118.63, Chaikin Money Flow : -0.06, MACD : 0.01, Money Flow Index : 80.75, ROC : 1.57, RSI : 58.20, STOCH (14,3) : 85.37, STOCH RSI : 1.00, UO : 54.27, Williams %R : -14.63), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of CytomX Therapeutics Inc. in the last 12-months were: Sean A. McCarthy (Option Excercise at a value of $190 377)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
9 (100.00 %)
8 (100.00 %)
8 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

CytomX Therapeutics Inc.

CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company which is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platform. The company probody technology platform to create proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of unique conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues. The company focuses on developing Probody therapeutics which addresses clinically-validated cancer targets in immuno-oncology that are difficult to drug and lead to concerns about damage to healthy tissues or toxicities.

CEO: Sean A. McCarthy

Telephone: +1 650 515-3185

Address: 151 Oyster Point Boulevard, South San Francisco 94080, CA, US

Number of employees: 146

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

57%43%

Bearish Bullish

59%41%

Bearish Bullish

62%38%

TipRanks News for CTMX

News

Stocktwits